Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
LucentisⓇ
-
Anti-VEGF
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT02640664 RAINBOW Extension (CRFB002H2301E1)
Retinopathy of Prematurity (ROP)
Phase 3
180
To evaluate the visual function of patients by assessing the visual acuity in the
better-seeing eye at the patient's fifth birthday.
Ranibizumab 0.2 mg (up to Week 40, if warranted)
Ranibizumab 0.1 mg (up to Week 40, if warranted)
Male and female preterm infants with bilateral retinopathy of prematurity (ROP) who
completed RAINBOW.
Target Patients
Read-out Milesstone(s)
2023
Publication
TBD
124 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation